CYTK Stock AnalysisCytokinetics, Incorporated · current price $72.17 (-7.41% today)
Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.
Reading CYTK’s price and volume history…
Checking the areas that decide this thesis…
AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.
Reading CYTK’s filings…
| Quarter | EPS | Est. | Surprise | Result |
|---|---|---|---|---|
| 2025-09-30 | $-1.54 | $-1.57 | +1.6% | Beat |
| 2025-12-31 | $-1.50 | $-1.37 | -9.7% | Miss |
| 2026-03-31 | $-1.67 | $-1.65 | -1.3% | Miss |
| 2026-06-30 | $-1.50 | $-1.60 | +6.3% | Beat |
Cytokinetics, Incorporated (CYTK) currently has a TickerMover Quant Score of 48/100, rated ★★ Below Avg. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.
TickerMover does not give buy or sell recommendations. CYTK scores 48/100 (★★ Below Avg) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.
CYTK's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.
Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.
Open the dashboard for CYTK →
